NasdaqGM - Delayed Quote USD

Altimmune, Inc. (ALT)

7.26 +0.06 (+0.83%)
At close: 4:00 PM EDT
7.27 +0.01 (+0.14%)
After hours: 7:25 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ALT

Recent News: ALT

View More
Altimmune Statement on the Passing of Dr. Stephen Harrison

Altimmune Statement on the Passing of Dr. Stephen Harrison
GlobeNewswire yesterday
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 30 days ago
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024

Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
GlobeNewswire last month
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024

Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
GlobeNewswire 3 months ago
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
GlobeNewswire 4 months ago
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update

Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
GlobeNewswire 5 months ago
Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023
GlobeNewswire 5 months ago
Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
GlobeNewswire 5 months ago
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023

Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
GlobeNewswire 5 months ago
Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune to Participate at Two Upcoming Investor Conferences
GlobeNewswire 6 months ago
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
GlobeNewswire 6 months ago
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
GlobeNewswire 7 months ago
View More

Related Tickers

VKTX Viking Therapeutics, Inc.
74.31
+7.91%
 
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%
 
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%
 
IBRX ImmunityBio, Inc.
7.35
+43.84%
 
ANVS Annovis Bio, Inc.
18.01
+32.43%
 
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%
 
TGTX TG Therapeutics, Inc.
13.47
-3.16%
 
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%
 
AXSM Axsome Therapeutics, Inc.
71.71
+0.27%
 
TERN Terns Pharmaceuticals, Inc.
4.9100
+5.82%